PARD3B: A Potential Drug Target and Biomarker (G117583)

Target Name: PARD3B

NCBI ID: G117583

PARD3B

PARD3B: A Potential Drug Target and Biomarker

Pardinib is an oral small molecule inhibitor of the B-cell maturation antigen (BMA) gene, which is expressed in many types of cancer cells. BMA is a transmembrane protein that is involved in the development and maintenance of normal B cells, which are responsible for producing antibodies to fight off infections and cancer. In individuals with B-cell malignancies, such as leukemia, BMA is often overexpressed, leading to the formation of cancerous B cells that are resistant to chemotherapy and targeted treatments.

The discovery and characterization of PARD3B as a potential drug target and biomarker for B-cell malignancies is a significant development in the field of cancer research. By targeting BMA with small molecules, scientists can develop new treatments that specifically target this protein and are less likely to affect healthy cells.

PARD3B is a gene that encodes a protein known as PARD3B, which is a key regulator of B-cell development and maturation. BPA1, a gene that encodes the BMA protein, is a known suppressor of PARD3B, which means that when BPA1 is expressed, it inhibits the activity of PARD3B. By inhibiting the activity of PARD3B, BPA1 can cause B cells to undergo a process called apoptosis, which is a natural form of cell death that helps remove damaged or dysfunctional cells from the body.

Research has shown that BPA1 is often overexpressed in various types of cancer cells, including B-cell malignancies. By inhibiting the activity of PARD3B, BPA1 can cause B cells to undergo apoptosis, leading to the formation of cancerous B cells that are resistant to chemotherapy and targeted treatments. This is why PARD3B has great potential as a drug target and biomarker for B-cell malignancies.

One of the key advantages of PARD3B as a drug target is its specificity. PARD3B is designed to target the B-cell maturation antigen (BMA) protein, which is a known regulator of B-cell development and maturation. This means that PARD3B is unlikely to affect other types of cells, which can reduce the risk of side effects and improve the overall effectiveness of the treatment.

Another advantage of PARD3B is its ability to cross the blood-brain barrier. The blood-brain barrier is a barrier that separates the brain from the blood and is designed to prevent the entry of harmful substances into the brain. However, some cancer treatments can bypass this barrier and enter the brain, leading to the formation of new tumors. PARD3B has been shown to be able to cross the blood-brain barrier, which gives it the potential to be used as a treatment for B-cell malignancies that have spread to the brain.

In addition to its potential as a drug target and biomarker, PARD3B is also a promising biomarker for B-cell malignancies. The formation of cancerous B cells that are resistant to chemotherapy and targeted treatments is associated with increased levels of BMA in the body. PARD3B has been shown to be highly expressed in various types of B-cell malignancies, including leukemia, and may be a useful biomarker for these cancers.

The identification and characterization of PARD3B as a potential drug target and biomarker for B-cell malignancies is a promising development in the field of cancer research. By targeting BMA with small molecules, scientists can develop new treatments that specifically target this protein and are less likely to affect healthy cells. Further research is needed to fully understand the potential of PARD3B as a drug target and biomarker for B-cell malignancies.

Protein Name: Par-3 Family Cell Polarity Regulator Beta

Functions: Putative adapter protein involved in asymmetrical cell division and cell polarization processes. May play a role in the formation of epithelial tight junctions

The "PARD3B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PARD3B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets